UB381
TargetsSTAT6
IndicationsAutoimmune disorder; Respiratory disorder
ClinicalCN - Pre-PCC
TherapeuticsImmunology & Inflammation
ModalitiesSmall Molecule
Exclusive Summary
- • A Potential Best-in-class STAT6 degrader.
- • In vitro activity reaches the picomolar (pM) level, significantly outperforming dupilumab.
- • Favorable oral exposure across various animal species.
- • Excellent degradation activity in animal models (in vivo).
- • Wide range of indications with huge MKT potential: AD,COPD, EoE etc.
Asset Materials
How can we help you?
Receive insights into the latest events and regulatory updates
Sent directly to your email
Get industry insights and Unibest news here
Contact Us →